At Dopavision, we strive to revolutionize the field of eye care by introducing a fresh perspective. Through the integration of selective ocular light stimulation and widely accessible consumer electronics, we activate the eye’s natural signaling pathways in a non-invasive way. Our mission is to tackle a critical global public health challenge and enable as many individuals as possible to enjoy a healthier and brighter future.
The product MyopiaX® by Dopavision is an innovative digital therapeutic solution aimed at slowing the progression of childhood myopia (nearsightedness). It utilizes patented light-based technology to stimulate photosensitive retinal cells, increasing dopamine levels, which play a critical role in regulating eye growth. The therapy is integrated into engaging digital experiences, such as games or educational content, making it convenient and appealing for children while requiring minimal parental supervision.
The device is designed to be used on standard digital devices, such as smartphones or tablets, and seamlessly integrates into daily routines. Dopavision has demonstrated the concept's effectiveness through preclinical studies, which show increased dopamine production, improved choroidal thickness, and inhibited myopia progression. Clinical trials are currently underway in Europe to further test its efficacy and safety, involving over 230 children across countries like Germany, Spain, and Ireland.
